Acelyrin, Inc Common Stock Price To Sales
| SLRN Stock | USD 3.25 0.07 2.11% |
ACELYRIN, INC Common fundamentals help investors to digest information that contributes to ACELYRIN, INC's financial success or failures. It also enables traders to predict the movement of ACELYRIN, Stock. The fundamental analysis module provides a way to measure ACELYRIN, INC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ACELYRIN, INC stock.
| Last Reported | Projected for Next Year |
ACELYRIN, |
ACELYRIN, INC Common Company Price To Sales Analysis
ACELYRIN, INC's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
ACELYRIN, Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for ACELYRIN, INC is extremely important. It helps to project a fair market value of ACELYRIN, Stock properly, considering its historical fundamentals such as Price To Sales. Since ACELYRIN, INC's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ACELYRIN, INC's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ACELYRIN, INC's interrelated accounts and indicators.
Click cells to compare fundamentals
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, ACELYRIN, INC Common has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to sales for all United States stocks is 100.0% higher than that of the company.
ACELYRIN, Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ACELYRIN, INC's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ACELYRIN, INC could also be used in its relative valuation, which is a method of valuing ACELYRIN, INC by comparing valuation metrics of similar companies.ACELYRIN, INC is currently under evaluation in price to sales category among its peers.
ACELYRIN, INC ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ACELYRIN, INC's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ACELYRIN, INC's managers, analysts, and investors.Environmental | Governance | Social |
ACELYRIN, Fundamentals
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | (229.76 M) | ||||
| Shares Outstanding | 100.33 M | ||||
| Shares Owned By Insiders | 8.03 % | ||||
| Shares Owned By Institutions | 99.45 % | ||||
| Number Of Shares Shorted | 5.99 M | ||||
| Price To Book | 0.62 X | ||||
| EBITDA | (381.53 M) | ||||
| Net Income | (381.64 M) | ||||
| Total Debt | 1.19 M | ||||
| Book Value Per Share | 5.29 X | ||||
| Cash Flow From Operations | (169.71 M) | ||||
| Short Ratio | 8.32 X | ||||
| Earnings Per Share | (2.46) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 135 | ||||
| Market Capitalization | 326.06 M | ||||
| Total Asset | 742.69 M | ||||
| Retained Earnings | (488.72 M) | ||||
| Working Capital | 651.48 M | ||||
| Net Asset | 742.69 M |
About ACELYRIN, INC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ACELYRIN, INC Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ACELYRIN, INC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ACELYRIN, INC Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ACELYRIN, INC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ACELYRIN, INC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ACELYRIN, INC will appreciate offsetting losses from the drop in the long position's value.Moving together with ACELYRIN, Stock
Moving against ACELYRIN, Stock
| 0.85 | DRTS | Alpha Tau Medical | PairCorr |
| 0.75 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.72 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.68 | VCYT | Veracyte | PairCorr |
| 0.65 | VCEL | Vericel Corp Ord | PairCorr |
The ability to find closely correlated positions to ACELYRIN, INC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ACELYRIN, INC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ACELYRIN, INC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ACELYRIN, INC Common to buy it.
The correlation of ACELYRIN, INC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ACELYRIN, INC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ACELYRIN, INC Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ACELYRIN, INC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out ACELYRIN, INC Piotroski F Score and ACELYRIN, INC Altman Z Score analysis. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACELYRIN, INC. If investors know ACELYRIN, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACELYRIN, INC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Return On Assets (0.33) | Return On Equity (0.42) |
The market value of ACELYRIN, INC Common is measured differently than its book value, which is the value of ACELYRIN, that is recorded on the company's balance sheet. Investors also form their own opinion of ACELYRIN, INC's value that differs from its market value or its book value, called intrinsic value, which is ACELYRIN, INC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACELYRIN, INC's market value can be influenced by many factors that don't directly affect ACELYRIN, INC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACELYRIN, INC's value and its price as these two are different measures arrived at by different means. Investors typically determine if ACELYRIN, INC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACELYRIN, INC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.